001     120030
005     20240228135008.0
024 7 _ |a 10.1093/nar/gku775
|2 doi
024 7 _ |a pmid:25159616
|2 pmid
024 7 _ |a pmc:PMC4231731
|2 pmc
024 7 _ |a 0261-3166
|2 ISSN
024 7 _ |a 0305-1048
|2 ISSN
024 7 _ |a 1362-4962
|2 ISSN
024 7 _ |a 1746-8272
|2 ISSN
024 7 _ |a altmetric:2634172
|2 altmetric
037 _ _ |a DKFZ-2017-00618
041 _ _ |a eng
082 _ _ |a 540
100 1 _ |a Öz, Aliye Simin
|0 P:(DE-He78)128bacd489143200b69fb6fd90b1c4d7
|b 0
|e First author
245 _ _ |a Quantitative determination of decitabine incorporation into DNA and its effect on mutation rates in human cancer cells.
260 _ _ |a Oxford
|c 2014
|b Oxford Univ. Press44364
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1490771885_9379
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Decitabine (5-aza-2'-deoxycytidine) is a DNA methyltransferase inhibitor and an archetypal epigenetic drug for the therapy of myeloid leukemias. The mode of action of decitabine strictly depends on the incorporation of the drug into DNA. However, DNA incorporation and ensuing genotoxic effects of decitabine have not yet been investigated in human cancer cell lines or in models related to the approved indication of the drug. Here we describe a robust assay for the quantitative determination of decitabine incorporation rates into DNA from human cancer cells. Using a panel of human myeloid leukemia cell lines we show appreciable amounts of decitabine incorporation that closely correlated with cellular drug uptake. Decitabine incorporation was also detectable in primary cells from myeloid leukemia patients, indicating that the assay is suitable for biomarker analyses to predict drug responses in patients. Finally, we also used next-generation sequencing to comprehensively analyze the effects of decitabine incorporation on the DNA sequence level. Interestingly, this approach failed to reveal significant changes in the rates of point mutations and genome rearrangements in myeloid leukemia cell lines. These results indicate that standard rates of decitabine incorporation are not genotoxic in myeloid leukemia cells.
536 _ _ |a 311 - Signalling pathways, cell and tumor biology (POF3-311)
|0 G:(DE-HGF)POF3-311
|c POF3-311
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antimetabolites, Antineoplastic
|2 NLM Chemicals
650 _ 7 |a DNA, Neoplasm
|2 NLM Chemicals
650 _ 7 |a decitabine
|0 776B62CQ27
|2 NLM Chemicals
650 _ 7 |a Azacitidine
|0 M801H13NRU
|2 NLM Chemicals
700 1 _ |a Raddatz, Günter
|0 P:(DE-He78)e712dff472bccab611dd1641f262ea5a
|b 1
700 1 _ |a Rius Montraveta, Maria
|0 P:(DE-He78)3d8673dc33aa3489cd27faea7d8786f5
|b 2
|u dkfz
700 1 _ |a Blagitko-Dorfs, Nadja
|b 3
700 1 _ |a Lübbert, Michael
|b 4
700 1 _ |a Maercker, Christian
|0 P:(DE-He78)53480a47ebf97fd693f02914400dbefb
|b 5
|u dkfz
700 1 _ |a Lyko, Frank
|0 P:(DE-He78)a8d53a8cdc716390a6cbacdead227143
|b 6
773 _ _ |a 10.1093/nar/gku775
|g Vol. 42, no. 19, p. e152 - e152
|0 PERI:(DE-600)2205588-5
|n 19
|p e152 - e152
|t Nucleic acids symposium series
|v 42
|y 2014
|x 1362-4962
909 C O |o oai:inrepo02.dkfz.de:120030
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)128bacd489143200b69fb6fd90b1c4d7
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)e712dff472bccab611dd1641f262ea5a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)3d8673dc33aa3489cd27faea7d8786f5
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)53480a47ebf97fd693f02914400dbefb
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)a8d53a8cdc716390a6cbacdead227143
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-311
|2 G:(DE-HGF)POF3-300
|v Signalling pathways, cell and tumor biology
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a Allianz-Lizenz / DFG
|0 StatID:(DE-HGF)0400
|2 StatID
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NUCLEIC ACIDS RES : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b NUCLEIC ACIDS RES : 2015
920 1 _ |0 I:(DE-He78)A130-20160331
|k A130
|l Epigenetik
|x 0
920 1 _ |0 I:(DE-He78)W110-20160331
|k W110
|l Microarray Unit
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)A130-20160331
980 _ _ |a I:(DE-He78)W110-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21